Numira Names Hal Widlansky As New CEO
SALT LAKE CITY
, Jan. 9, 2014
/PRNewswire/ -- Numira, a leader in high resolution, 3D imaging services, visualization software, and cloud computing for the life science market, today announced the appointment of Hal Widlansky
as Chief Executive Officer.
"We chose Hal not only for his broad background in new technology, but also because of his reputation for aligning organizations to execute on a unified strategy," said Lisa Dunlea, Venture Partner at Signal Peak Ventures and Numira board member. "With Hal, we have found the right CEO to take Numira to the next level, his go-to-market experience is just what the company needs in this next phase of growth."
Prior to taking the helm at Numira, Widlansky served as President and COO of Radiate Media, a digital and broadcast media company recently recognized, for the second consecutive year, as Utah's fastest growing company at the Mountain West Capital Network's (MWCN) Utah 100 Awards. Before Radiate, he served as CEO of Matchbin, a digital media and advertising organization, responsible for the company's acquisition of Nokia's broadcast advertising unit, the merger that would form Radiate Media. Additionally, Hal has served as CEO of Mangia Technologies, a mobile technology company; CEO of SonoMetric Health, a medical software company; and Global Director of SonoSite Ultrasound's cardiology unit.
"Few companies are as well poised for significant growth as Numira," said Hal. "Our focus on execution in product, services, and technology development has established us as a leader in imaging and quantitative analysis for the pharmaceutical and biotech industries. I look forward to working with our phenomenal team in building upon our impeccable reputation and driving growth for our company. I am honored to have been chosen by the board to lead Numira into this next exciting new chapter."
Numira is a rapidly growing provider of specialty contract research services to the pharmaceutical and medical device industries. Through the combination of novel software technologies and unique imaging capabilities, Numira provides clients with an unmatched array of pre-clinical services for research programs in inflammation, cardiovascular, oncology, pulmonary, renal, bone, and other therapeutic areas. Numira is a recognized leader in high-resolution imaging and specialized histology services for drug and device development.
For more information visit www.numira.com.